natgillin/translations-raw huggingface dataset:
Key secondary endpoints included the proportion of patients who achieved the primary endpoint and remained free from progression at week 48, as well as the proportion of patients achieving complete haematological remission at week 32.
Ključni sekundarni ishodi uključivali su udio bolesnika koji su postigli primarni ishod i nisu imali progresiju do 48. tjedna, kao i udio bolesnika koji su postigli potpunu hematološku remisiju do 32. tjedna.
Key secondary endpoints of major bleeding and all cause death were tested in a pre-specified hierarchical testing strategy to control the overall type 1 error in the trial.
Ključne sekundarne mjere ishoda – veliko krvarenje i smrt zbog bilo kojega razloga, ispitane su prethodno utvrđenom strategijom hijerarhijskog testiranja da bi se u cijelosti mogla kontrolirati pojavnost pogreške tipa 1 u ispitivanju.
Key Secondary Endpointsa, f,
Ključne sekundarne mjere ishodaa,f
Key signs and symptoms of intravitreal injection related adverse events including endophthalmitis, increased intraocular pressure, retinal injury, intraocular haemorrhage, traumatic cataract, hypersensitivity and injection of excess volume
ključne znakove i simptome štetnih događaja povezanih s intravitrealnim injekcijama uključujući endoftalmitis, povišeni intraokularni tlak, ozljedu mrežnice, intraokularno krvarenje, traumatsku kataraktu, preosjetljivost i injiciranja suvišnog volumena
Key signs and symptoms of intravitreal injection related adverse events including endophthalmitis, increased intraocular pressure, retinal pigment epithelial tear and cataract
Ključni znakovi i simptomi nuspojava povezanih s intravitrealnim injekcijama uključujući endoftalmitis, povišen intraokularni tlak, razderotina pigmentnog epitela mrežnice i katarakta
Key signs and symptoms of IVT injection related adverse events including increased intraocular pressure, glaucoma, ocular hypertension, cataract, traumatic cataract related to injection technique, vitreous detachment, vitreous haemorrhage, endophthalmitis, retinal detachment, retinal tear, device dislocation and implant misplacement
Glavne znakove i simptome štetnih događaja povezanih uz intravitrealno ubrizgavanje, uključujući povišeni očni tlak, glaukom, očnu hipertenziju, kataraktu, traumatsku kataraktu povezanu uz tehniku ubrizgavanja, odvajanje staklastog tijela, krvarenje staklastog tijela, endoftalmitis, ablaciju mrežnice, rupturu mrežnice, pomak instrumenta i krivi položaj implantata
Key signs and symptoms of IVT injection related adverse events including increased intraocular pressure, traumatic cataract and endophthalmitis
Ključni znakovi i simptomi štetnih događaja povezanih s IVT injekcijom koji uključuju povišeni intraokularni tlak, traumatsku kataraktu i endoftalmitis
Key signs and symptoms of myocardial infarction, VTE and serious skin reactions.
Ključne znakove i simptome infarkta miokarda, VTE i ozbiljnih kožnih reakcija.
Key signs and symptoms of serious adverse events
Bitni znakovi i simptomi ozbiljnih štetnih događaja
Key signs and symptoms of serious adverse events
Ključni znakovi i simptomi ozbiljnih štetnih događaja
Key signs and symptoms of serious adverse events
Ključnim znakovima i simptomima ozbiljnih štetnih događaja
Key signs and symptoms of serious adverse events including endophthalmitis, intraocular pressure increased, retinal pigment epithelial tear and cataract
Ključni znakovi i simptomi ozbiljnih nuspojava uključujući endoftalmitis, povišen intraokularni tlak, krvarenje u spojnicu, bol u oku, odvajanje staklovine, “mušice” u staklovini, razderotina pigmentnog epitela mrežnice i traumatska katarakta.
Key signs and symptoms of serious adverse events including increased intraocular pressure, traumatic cataract and endophthalmitis
Ključni znakovi i simptomi ozbiljnih štetnih događaja koji uključuju povišeni intraokularni tlak, traumatsku kataraktu i endoftalmitis
Key signs and symptoms of serious adverse events including: worsening of vision after the injection; pain or discomfort in or around the eye, redness of the eye which continues to get worse; increase in floaters or spots in the vision; discharge from the eye
Glavne znakove i simptome ozbiljnih štetnih događaja, uključujući: pogoršanje vida nakon injekcije; bol ili nelagodu u oku ili oko oka; crvenilo oka koje se i dalje pogoršava; povećan broj opaciteta ili točkica u vidnom polju; iscjedak iz oka.
Key signs and symptoms of serious adverse reactions
Ključne znakove i simptome ozbiljnih nuspojava
Key signs and symptoms of serious adverse reactions
Ključni znakovi i simptomi ozbiljnih nuspojava
KEY: AZA = azacitidine; CCR = conventional care regimens; CI = confidence interval; HR = hazard ratio
KRATICE: AZA = azacitidin; CCR = režim konvencionalne skrbi; CI = interval pouzdanosti; HR = omjer rizika
Key: Grey matter – f frontal and ac anterior cingulate, pc posterior cingulate and precuneus, lt lateral temporal, tp temporo-parietal and in insula and and s striatum.
Oznake: siva tvar – f frontalno i ac prednje cingulatno, pc stražnje cingulatno i prekuneus, lt lateralno temporalno, tp temporo-parijetalno i in insula i s strijatum.
Key: HoFH = homozygous familial hypercholesterolaemia; QM = once monthly; a nominal p value <0.001 when compared with placebo; b p value < 0.001 when compared with placebo.
Legenda: QM = jedanput mjesečno a nominalna p vrijednost < 0,001 pri usporedbi s placebom; b p vrijednost < 0,001 pri usporedbi s placebom
Key: OLE = open-label extension, N (n) = Number of evaluable patients (N) and patients with observed LDL values at specific scheduled visit (n) in the severe familial hypercholesterolaemia interim analysis set
Legenda: OLE = otvoreni produžetak ispitivanja, N (n) = broj procijenjivih bolesnika (N) i bolesnika s uočenim LDL vrijednostima mjerenim pri sprecifičnim zakazanim posjetima (n) u setu interim analize za tešku obiteljsku hiperkolesterolemiju
Key: Q2W = once every 2 weeks, QM = once monthly, HMD = Primary hypercholesterolaemia and mixed dyslipidaemia,a p value < 0.05 when compared with ezetimibe, b p value < 0.001 when compared with ezetimibe, c nominal p value < 0.001 when compared with ezetimibe.
Legenda: Q2W = jedanput svaka 2 tjedna, QM = jedanput mjesečno, HMD = Primarna hiperkolesterolemija i miješana dislipidemija; a p vrijednost < 0,05 pri usporedbi s ezetimibom. b p vrijednost < 0,001 pri usporedbi s ezetimibom, c nominalna p vrijednost < 0,001 pri usporedbi s ezetimibom.
Key: Q2W = once every 2 weeks, QM = once monthly, HMD = Primary hypercholesterolaemia and mixed dyslipidaemia; HeFH = Heterozygous familial hypercholesterolaemia; a p value < 0.05 when compared with placebo. b p value < 0.001 when compared with placebo.
Legenda: Q2W = jedanput svaka 2 tjedna, QM = jedanput mjesečno, HMD = Primarna hiperkolesterolemija i miješana dislipidemija; HeFH = Heterozigotna obiteljska hiperkolesterolemija; a p vrijednost < 0,05 pri usporedbi s placebom. b p vrijednost < 0.001 pri usporedbi s placebom.
Key: QM = once monthly, a nominal p value < 0.001 when compared with placebo, b p value < 0.001 when compared with placebo.
Legenda: QM = jedanput mjesečno a nominalna p vrijednost < 0,001 pri usporedbi s placebom. b p vrijednost < 0,001 pri usporedbi s placebom
Key:  reduced, ↑ increased,  unchanged, ↑↑ markedly increased
Ključ:  sniženo, ↑ povišeno,  nepromijenjeno, ↑↑ značajno povišeno
KEYNOTE-002: Controlled trial in melanoma patients previously treated with ipilimumab
KEYNOTE-002: Kontrolirano ispitivanje u bolesnika s melanomom koji su prethodno liječeni ipilimumabom
KEYNOTE-006: Controlled trial in melanoma patients naïve to treatment with ipilimumab
KEYNOTE-006: Kontrolirano ispitivanje u bolesnika s melanomom koji prethodno nisu liječeni ipilimumabom
KEYTRUDA can cause harm or death to your unborn baby.
KEYTRUDA može naškoditi nerođenu djetetu ili uzrokovati njegovu smrt.
Keytruda has been shown to be effective in treating patients with melanoma and non-small cell lung cancer.
Lijek Keytruda pokazao se djelotvornim u liječenju bolesnika oboljelih od melanoma i raka nemalih stanica pluća.
KEYTRUDA has not been studied in patients with moderate or severe hepatic impairment (see section 5.2).
KEYTRUDA se nije ispitivala u bolesnika s umjerenim ili teškim oštećenjem funkcije jetre (vidjeti dio 5.2).
KEYTRUDA has not been studied in patients with severe renal impairment (see section 5.2).
KEYTRUDA se nije ispitivala u bolesnika s teškim oštećenjem funkcije bubrega (vidjeti dio 5.2).
Keytruda is a cancer medicine used to treat adults with:
Lijek Keytruda je citostatik koji se koristi za liječenje odraslih osoba oboljelih od:
Keytruda is available as a powder that is made up into a solution for infusion (drip) into a vein.
Lijek Keytruda dostupan je kao prašak koji se koristi za pripremu otopine za infuziju (drip) u venu.
KEYTRUDA is for single use only.
KEYTRUDA je namijenjena isključivo za jednokratnu uporabu.
KEYTRUDA is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen.
KEYTRUDA je indicirana za liječenje lokalno uznapredovalog ili metastatskog karcinoma pluća nemalih stanica (engl. non-small cell lung carcinoma, NSCLC) u odraslih čiji tumori eksprimiraju PD-L1 i koji su prethodno primili najmanje jedan kemoterapijski protokol.
Keytruda is specifically for lung tumours that produce a protein known as PD-L1.
Lijek Keytruda namijenjen je posebno za tumore pluća koji proizvode bjelančevinu PD-L1.
KEYTRUDA should be permanently discontinued:
Liječenje lijekom KEYTRUDA mora se trajno prekinuti:
KEYTRUDA should not to be used in children and adolescents below 18 years of age.
KEYTRUDA se ne smije primjenjivati u djece i adolescenata mlađih od 18 godina.
Keytruda was also effective in the larger group of patients with lung cancer, including those whose tumours were not strongly positive for PD-L1.
Lijek Keytruda također se pokazao djelotvornim u većoj skupini bolesnika oboljelih od raka pluća, uključujući one u čijim tumorima nije pronađena veća količina bjelančevine PD-L1.
Kg Premix/tonne feed
kg predmješavine/tona hrane
Kg Premix/tonne feed
Kg predmješavine/tona hrane za životinje
KGF receptors are known to be expressed on the lens of the eye.
Poznato je da su receptori za čimbenike rasta keratinocita izraženi na stanicama očne leće.
Ki values in human liver microsomes were 27, 7.5 and 7.9 µmol/l, respectively.
Ki vrijednosti u jetrenim mikrosomima čovjeka bile su 27, 7,5, odnosno 7,9 mol/l.
Ki values in human liver microsomes were 27, 7.5 and 7.9 μmol/l, respectively.
Ki vrijednosti u jetrenim mikrosomima čovjeka bile su 27, 7,5, odnosno 7,9 mol/l.
Kidney
Bubrezi
Kidney (renal) disease, since your doctor may need to check the dose of your other medicines (such as protease inhibitors).
Bolest bubrega, jer će Vaš liječnik možda trebati provjeriti doze drugih lijekova koje uzimate (npr. inhibitori proteaza).
Kidney and liver graft rejection
Odbacivanje presatka bubrega i jetre
Kidney and liver problems
Tegobe s bubrezima i jetrom
kidney and urinary problems including impairment of kidney function, blood in the urine and urinary disturbances
bubrežne i urinarne smetnje uključujući oštećenje funkcije bubrega, krv u mokraći i smetnje mokrenja
kidney cancer that is advanced or has spread to other organs. certain forms of soft tissue sarcoma a type of cancer that affects the supportive tissues of the body.
karcinoma bubrega koji je uznapredovao ili se proširio na druge organe. određenih oblika sarkoma mekih tkiva, vrste raka koja zahvaća potporna tkiva u tijelu.
kidney changes, characterized by slight increases in serum urea and creatinine, and hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the interaction of irbesartan with the renin-angiotensin system;
promjene funkcije bubrega, karakterizirane blagim porastom razine ureje i kreatinina u serumu kao i hiperplazija/hipertrofija jukstaglomerularnog aparata, što je izravna posljedica interakcije irbesartana s renin-angiotenzinskim sustavom;
Kidney damage with low blood cell counts (thrombocytopaenic purpura/haemolytic uraemic syndrome)
Oštećenje bubrega sa sniženim brojem krvnih stanica (trombocitopenična purpura/hemolitičko- uremijski sindrom)
Kidney damage with low blood platelets and low red blood cell counts, with or without rash (haemolytic uraemic syndrome)
oštećenje bubrega s niskim brojem krvnih pločica i niskim brojem crvenih krvnih stanica, s osipom ili bez osipa (hemolitičko-uremijski sindrom)
Kidney disease
bolest bubrega
Kidney disease (renal failure).
bolest bubrega (zatajenje bubrega)
Kidney disease (such as anti-GBM disease)
Bolest bubrega (poput anti-GBM bolesti)
Kidney disease or kidney transplant
Bolest bubrega ili transplantacija bubrega.
Kidney disease or kidney transplant.
bolest bubrega ili presađeni bubreg.
Kidney disease or kidney transplant.
Bolest bubrega ili transplantacija bubrega.
Kidney disease or kidney transplant.
Bolest bubrega ili transplatacija bubrega.
kidney disease or problems
bubrežna bolest ili tegobe s bubrezima
Kidney disease patients
Bolesnici s bolestima bubrega
Kidney disease that is caused by a virus (polyomavirus-associated nephropathy), inflammation of the kidneys, scarring of the kidneys, shrinkage of the small tubes in the kidney, inflammation of the bladder with bleeding
Bolest bubrega koja je prouzročena virusom (nefropatija povezana s poliomavirusom), upala bubrega, stvaranje ožiljaka u bubregu, sužavanje kanalića u bubregu, upala mokraćnog mjehura s krvarenjem
Kidney disease.
Bolest bubrega.
Kidney disease.
Bolesti bubrega
Kidney disease.
Bolesti bubrega.
Kidney disease: Consult your doctor if you have a history of kidney disease.
Bolest bubrega: Posavjetujte se s liječnikom ako ste nekada imali bolest bubrega.
kidney disorder, abnormal kidney function tests, foamy urine tiredness, chills
oštećenje bubrega, abnormalni rezultati pretraga funkcije bubrega, pjenušava mokraća umor, zimica
kidney disorder, blood in urine, difficulties or pain when urinating (dysuria)
poremećaj bubrega, krv u mokraći, poteškoće ili bol pri mokrenju (dizurija)
Kidney disorders (e.g. decreased urine output) may occur.
Mogu se pojaviti poremećaji bubrega (npr. smanjeno mokrenje).
kidney disorders confusion
poremećaji bubrega smetenost
kidney disorders  abnormal thinking
poremećaji bubrega  poremećeno razmišljanje
kidney disorders, (rare – may affect up to 1 in 1,000 people): may show as blood in the urine (your urine may be red or tea-coloured), or as swelling in your legs or feet.
poremećaji bubrega (rijetko – mogu se javiti u manje od 1 na 1000 osoba): može se manifestirati kao krv u mokraći (mokraća može biti crvena ili boje čaja), ili kao oticanje nogu ili stopala.
Kidney disorders.
Poremećaji bubrega.
kidney failure
zatajenje bubrega
kidney failure severe vision loss
zatajenje bubrega težak gubitak vida
Kidney failure – common
zatajenje bubrega – često
kidney failure,
zatajenje bubrega,
Kidney failure, blood or protein in the urine
zatajenje bubrega, krv ili bjelančevine u mokraći
kidney failure, chest pain, feeling tired or sleepy.
zatajenje bubrega, bolovi u prsima, osjećaj umora ili pospanosti.
kidney failure, high blood pressure, heart attack, diabetes; night sweats.
zatajenje bubrega, visoki krvni tlak, srčani udar, šećerna bolest; noćna znojenja.
Kidney failure, inflammation of kidneys
zatajenje bubrega, upala bubrega
kidney failure, kidney stones, difficult discharge of urine, frequent or excessive passage of urine, sometimes at night
zatajenje bubrega, bubrežni kamenci, otežano mokrenje, često ili prekomjerno mokrenje, katkad i noću
Kidney failure, reduced urine volume, urinary retention
zatajenje bubrega, smanjen volumen mokraće, zadržavanje mokraće
Kidney failure, reduced urine volume, urinary retention.
zatajenje bubrega, smanjen volumen mokraće, zadržavanje mokraće
Kidney failure.
zatajenje bubrega
Kidney failure.
zatajenje bubrega.
Kidney failure.
zatajenje bubrega;
kidney failure;
zatajenje bubrega;
Kidney function and histology were similarly not affected both in 4- and 26-week studies.
Slično nije promijenjena ni funkcija bubrega niti su nastale histološke promjene na bubregu, kako tijekom 4-tjednog, tako i tijekom 26-tjednog ispitivanja.
kidney function failure, kidney disease
zatajenje funkcije bubrega, bolest bubrega
Kidney infection
infekcija bubrega
Kidney infection.
infekcija bubrega.
Kidney infections
infekcije bubrega
Kidney injury has been seen in patients who received filgrastim.
Ozljeda bubrega primijećena je kod bolesnika koji su primili filgrastim.
Kidney Liver Muscle
Bubreg Jetra Mišić
kidney or hormone-related diseases
bolesti povezane s bubrezima ili hormonima,
kidney or liver problems
bubrežne ili jetrene probleme
kidney or liver problems an infection.
imate probleme s bubrezima ili jetrom imate infekciju.
kidney pain
bol u bubregu
kidney pain
bol u bubrezima
kidney problem with an increase in creatinine (a marker of kidney function) liver problem with an increase in liver enzymes.
tegobe s bubrezima uz povišene vrijednosti kreatinina (biljega bubrežne funkcije) tegobe s jetrom uz povišene vrijednosti jetrenih enzima.
kidney problems
poteškoće s bubrezima
kidney problems
problemi s bubrezima
kidney problems
problemi sa bubrezima
kidney problems
tegobe s bubrezima
kidney problems (including inflammation of the kidneys, kidney stones, or back pain with or without blood in your urine)
tegobe s bubrezima (uključujući upalu bubrega, bubrežne kamence ili bol u leđima koja može, ali i ne mora biti praćena krvlju u mokraći)
kidney problems (including nephritis)
problemi s bubrezima (uključujući nefritis)
Kidney problems (increased or decreased levels of certain enzymes within the body seen in a test) bladder problems (painful or frequent urination, having to pass water at night), sexual dysfunction.
Problemi s bubrezima (povišene ili snižene razine određenih enzima unutar tijela u krvnim nalazima), problemi s mokraćnim mjehurom (bolno ili učestalo mokrenje, potreba za mokrenjem noću), poremećaj seksualne funkcije.
kidney problems including acute renal failure (severely decreased urine output)
problemi s bubrezima, uključujući akutno zatajenje bubrega (jako smanjeno izlučivanje mokraće)
kidney problems including scarring (glomerulosclerosis) that may reduce your kidney function, (uncommon).
problemi s bubrezima uključujući stvaranje ožiljaka (glomeruloskleroza) koje može smanjiti funkciju Vaših bubrega (manje često).
kidney problems including scarring (glomerulosclerosis) that may reduce your kidney function, uncommon
problemi s bubrezima uključujući stvaranje ožiljaka (glomeruloskleroza) koji mogu smanjti funkciju Vaših bubrega, manje često
Kidney problems including scarring that may reduce your kidney function
Tegobe s bubrezima uključujući stvaranje ožiljaka koji mogu smanjiti funkciju Vaših bubrega
Kidney problems including scarring that may reduce your kidney function If you get some or all of these symptoms:
Problemi s bubrezima uključujući ožiljke koji mogu smanjiti funkciju Vaših bubrega Ako Vam se pojave neki ili svi ovi simptomi:
Kidney problems including scarring that may reduce your kidney function.
Problemi s bubrezima uključujući nastanak ožiljaka koji mogu oslabiti njihovu funkciju.
kidney problems including: inflammation of the kidney, excessive urination at night, kidney failure, urinary tract infection, white cells in urine
problemi s bubrezima uključuju: upalu bubrega, pojačano mokrenje noću, zatajenje bubrega, infekciju mokraćnih putova, prisutnost bijelih krvnih stanica u mokraći
Kidney problems may lead to softening of the bones (which causes bone pain and sometimes leads to fractures) and muscle pain or weakness.
problemi s bubrezima mogu uzrokovati omekšavanje kostiju (što uzrokuje bol u kostima a ponekad i prijelom) te bol u mišićima ili slabost.
kidney problems or difficulty passing urine abnormal blood brain barrier (the layer of cells surrounding the brain)
probleme s bubrezima ili otežano mokrenje abnormalnu krvno-moždanu barijeru (sloj stanica koji okružuje mozak)
kidney problems such as kidney infection, worsening or loss of kidney function pain and difficulty moving shoulder.
tegobe s bubrezima, poput infekcije bubrega, pogoršanja ili gubitka funkcije bubrega bol i poteškoće pri pomicanju ramena.
Kidney problems with increased levels of urea
problemi s bubrezima, uz povišene razine uree
Kidney problems – very common
probleme s bubrezima – vrlo često
Kidney problems,
problemi s bubrezima,
Kidney problems, as shown by blood tests
problemi s bubrezima koji su vidljivi i u krvnim pretragama
Kidney problems, including kidney failure
Problemi s bubrezima, uključujući zatajenje bubrega
Kidney problems, including kidney failure or if you have ever received dialysis
Problemi s bubrezima, uključujući zatajenje bubrega ili ako ste ikada primali dijalizu
kidney problems, since Harvoni has not been fully tested in patients with severe kidney problems;
tegobe s bubrezima, budući da Harvoni nije u potpunosti ispitan u bolesnika s teškim tegobama s bubrezima;
kidney problems;
poteškoće s bubrezima;
Kidney problems;
problemi s bubrezima,
kidney problems;
problemi sa bubrezima,
Kidney stones
Bubrežni kamenci
kidney stones erectile difficulties
bubrežni kamenci erektilna disfunkcija
kidney stones fever
bubrežni kamenci vrućica
Kidney stones have been reported in patients taking atazanavir, a component of EVOTAZ.
U bolesnika koji su uzimali atazanavir, sastojak lijeka EVOTAZ, prijavljeni su bubrežni kamenci.
kidney stones pain in the muscles and pain in the joints.
bubrežni kamenci bol u mišićima i zglobovima.
kidney stones underactive thyroid.
bubrežni kamenci smanjena aktivnost štitne žlijezde
kidney stones, dehydration (loss of too much fluid from your body).
bubrežni kamenci, dehidracija (gubitak prevelike količine tekućine iz tijela).
kidney stones, sugar (glucose) in urine
bubrežni kamenci, šećer (glukoza) u mokraći
kidney stones.
bubrežni kamenci
kidney stones; urination at night; kidney cyst
bubrežni kamenci; mokrenje noću; bubrežna cista
Kidney tests or checks
Kontrole bubrežne funkcije
kidney,
bubrega,
Kidney: abnormal blood tests
Bubreg: poremećeni nalazi krvnih pretraga
Kidney: decreased urine volume, changes in blood tests which show the way the kidney is working, kidney impairment and failure
Bubrege: smanjen volumen urina, promjene u nalazima krvi koji ukazuju na rad bubrega, oštećenje i zatajenje bubrega
Kidney: decreased urine volume, changes in blood tests which show the way the kidney is working, kidney impairment and failure
Bubrege: smanjen volumen urina, promjene u nalazima krvi koji ukazuju na rad bubrega, oštećenje i zatajenje bubrega.
Kidney: kidney pain such as lower back pain, frequent urination.
Bubrezi: bol u bubrezima, npr. bol u donjem dijelu leđa, učestalo mokrenje.
Kidney: renal impairment (generally reversible after conclusion of treatment)
Bubreg: oštećenje funkcije bubrega (u načelu se povlači nakon završetka liječenja)
kidneys unable to remove acids from blood normally presence of antibodies in the blood against some of your own cells
nesposobnost bubrega da normalno uklone kiseline iz krvi prisutnost protutijela na neke stanice vlastitog organizma u krvi.
Kidneys1
Bubrezi1
Killorglin, County Kerry Ireland
Killorglin, County Kerry Irska
kin
koža
kin adhesive: polybutene, polyisobutylene, and rosin ester protective liner: polyester film coated on one side with silicone.
ljepilo za kožu: polibuten, poliizobutilen i ester kolofonija zaštitna podloga: poliesterski film s jedne strane obložen silikonom.
kin allergy
kožna alergija
kin bleeding
krvarenje iz kože
kin boils
gnojne upale
kin bruising
modrice na koži,
kin cancer
rak kože
kin cancer (squamous cell carcinoma)
rak kože (planocelularni karcinom)
kin cancer (uncommon).
rak kože (manje često).
kin cancer excluding melanoma (including
rak kože, isključujući melanom (uključujući
kin cancer excluding melanoma (including basal cell carcinoma and squamous cell carcinoma), benign neoplasm
rak kože, isključujući melanom (uključujući bazocelularni karcinom i karcinom skvamoznih stanica),
kin cancer, skin warts
rak kože, kožne bradavice
kin cancer;
rak kože,
kin cancers, pre-cancerous skin lesions
zloćudni tumori kože, prekancerozne kožne lezije